Oncorena
Stage
Unattributed VC - II | AliveTotal Raised
$8.85MLast Raised
$7.26M | 1 yr agoAbout Oncorena
Oncorena develops a drug based on the natural substance orellanine, a highly kidney selective toxin from certain mushrooms. The therapeutic concept is to treat patients with metastasized renal clear cell cancer in dialysis with orellanine.
Missing: Oncorena's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Oncorena's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Oncorena
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Oncorena is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Cancer
3,605 items
Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.
Oncorena Patents
Oncorena has filed 2 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/28/2011 | 4/14/2015 | Kidney cancer, Polysaccharides, Oncology, Cancer treatments, Dermal and subcutaneous growths | Grant |
Application Date | 3/28/2011 |
|---|---|
Grant Date | 4/14/2015 |
Title | |
Related Topics | Kidney cancer, Polysaccharides, Oncology, Cancer treatments, Dermal and subcutaneous growths |
Status | Grant |
Latest Oncorena News
Jun 22, 2022
Yerxa leaving Foundation Fighting Blindness to become Opus’ permanent CEO Plus Biden to nominate Arati Prabhakar as director of OSTP, and updates from Oncorena, Panorama, Indivior, Prolacta and more By Richard Guy, Biopharma Analyst and Gunjan Ohri, Data Content Analyst June 22, 2022 12:49 AM UTC Foundation Fighting Blindness CEO Ben Yerxa will become permanent CEO at Opus Genetics Inc. — the first company to spin out from the foundation and its venture arm, the Retinal Degeneration ... Access this Article
Oncorena Frequently Asked Questions (FAQ)
Where is Oncorena's headquarters?
Oncorena's headquarters is located at Kullagatan 8, Helsingborg.
What is Oncorena's latest funding round?
Oncorena's latest funding round is Unattributed VC - II.
How much did Oncorena raise?
Oncorena raised a total of $8.85M.
Who are the investors of Oncorena?
Investors of Oncorena include HealthCap Venture Capital, Linc Invest, FSG Fond and Aqilion.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.